ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,967.23
-0.88%
US Tech 100
16,554.00
-2.26%
Dow Jones
37,986.40
0.56%
Brent Oil
86.625
0.00%
Bitcoin
63,903.14
0.12%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Zentalis Pharmaceuticals Inc (ZNTL) Quote

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc (ZNTL)

NASDAQ
12.96
0.42
(3.35%)
Closed April 20 4:00PM
Delayed by 15 minutes
12.96
0.00
(0.00%)
After Hours: 4:15PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
12.96
Bid
12.96
Ask
14.89
Volume
1,007,879
12.30 Day's Range 13.07
9.56 52 Week Range 31.46
Market Cap
921.773M
Previous Close
12.54
Open
12.48
Last Trade
114
@
12.96
(formt)
Last Trade Time
Financial Volume
$ 12,805,300
VWAP
12.7052
Average Volume (3m)
836,446
Shares Outstanding
70,960,165
Dividend Yield
-
PE Ratio
-3.15
Earnings Per Share (EPS)
-4.12
Revenue
-
Net Profit
-292.19M

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.zentalis.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Zentalis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was $12.54. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of $ 9.56 to $ 31.46.

Zentalis Pharmaceuticals currently has 70,960,165 shares outstanding. The market capitalization of Zentalis Pharmaceuticals is $921.77 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.15.

ZNTL Latest News

More News

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

NEW YORK and SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...

April 02 2024
GlobeNewswire Inc.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...

April 01 2024
GlobeNewswire Inc.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...

March 01 2024
GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans

February 29 2024
Edgar (US Regulatory)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

February 29 2024
Edgar (US Regulatory)

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...

February 28 2024
GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

February 27 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 27 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.25-1.8925056775213.2114.0712.371805812.99090823CS
4-0.88-6.3583815028913.8416.26512.366250414.27698908CS
12-0.29-2.1886792452813.2518.0710.5783644613.77220888CS
26-5.37-29.296235679218.3318.339.5696811313.4066431CS
52-6.88-34.677419354819.8431.469.5688066718.58688342CS
156-36.92-74.017642341649.8887.199.5661609127.04464871CS
260-11.73-47.509113001224.6987.199.5652197829.03665015CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

ZNTL Discussion

View Posts
ANTADOG ANTADOG 4 years ago
We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
👍️0
ANTADOG ANTADOG 4 years ago
Added some 46's , nice chart reset, ANT
👍️0
ANTADOG ANTADOG 4 years ago
55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
👍️0
ANTADOG ANTADOG 4 years ago
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
👍️0
ANTADOG ANTADOG 4 years ago
NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
fyi ANT
👍️0
ANTADOG ANTADOG 4 years ago
New 52 week high at 52.09, i luv it, ANT
👍️0
ANTADOG ANTADOG 4 years ago
Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
fyi ANT
👍️0
ANTADOG ANTADOG 4 years ago
Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
👍️0
ANTADOG ANTADOG 4 years ago
promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
👍️0
crudeoil24 crudeoil24 4 years ago
ZNTL opens @ 25.20 >
👍️0
crudeoil24 crudeoil24 4 years ago
Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher

Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2020 06:08 ET (10:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
👍️0
crudeoil24 crudeoil24 4 years ago
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
👍️0

Your Recent History

NASDAQ
ZNTL
Zentalis Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved